|Bid||0.0000 x 4000|
|Ask||0.0000 x 4000|
|Day's Range||2.7950 - 2.9500|
|52 Week Range||2.5000 - 6.7900|
|Beta (5Y Monthly)||1.13|
|PE Ratio (TTM)||156.11|
|Earnings Date||Mar 14, 2022 - Mar 18, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
Subscribe to Yahoo Finance Plus to view Fair Value for AGENLearn more
Shares of the small-cap immunotherapy company Agenus (NASDAQ: AGEN) were exceedingly volatile over the whole of 2021. Turning to the specifics, Agenus' stock first gained a healthy 55% during the first month of the year, before giving back all of these gains plus another 10%, according to data provided by S&P Global Market Intelligence . In May 2021, Agenus' stock went on a second major rally, with the drugmaker's shares more than doubling in value from their intra-year lows.
Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.
LEXINGTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that management will participate in the following upcoming investor conferences: H.C. Wainwright Bioconnect Conference – presentation will be available on-demand from Monday, January 10, 2022 from 7:00 AM ESTB. Riley Securities’ 2022 Virtual